Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 4/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23226812 | 0.93 | DRD1 (0.57) | TYRDRD1CYP2A6HSD17B10ALDH5A1 | |
| SCHEMBL5562562 | 0.84 | TYR (0.44) | TYRDRD1CYP2A6HSD17B10ALDH5A1 | |
| SCHEMBL7140081 | 0.80 | TYR (0.54) | TYRDRD1CYP2A6HSD17B10ALDH5A1 | |
| SCHEMBL6819315 | 0.78 | TYR (0.47) | TYRDRD1CYP2A6ALDH1A1ALDH1A3 | |
| SCHEMBL1915552 | 0.78 | TYR (0.64) | TYRDRD1CYP2A6HSD17B10ALDH5A1 | |
| SCHEMBL21402627 | 0.77 | ALDH1A1 (0.54) | TYRALDH1A1KDM4E | |
| SCHEMBL4914733 | 0.77 | TYR (0.50) | TYRDRD1CYP2A6HSD17B10ALDH5A1 | |
| SCHEMBL6819485 | 0.77 | TYR (0.50) | TYRDRD1CYP2A6ALDH1A1ALDH1A3 | |
| SCHEMBL662302 | 0.76 | PGK1 (0.38) | — | |
| SCHEMBL4956384 | 0.76 | CYP2A6 (0.69) | TYRCYP2A6HSD17B10ALDH5A1ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662208-A1 | COMPOUNDS AND COMPOSITIONS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-116535327-B | Method for improving stability of aromatic difluoromethyl compound in preparation and use | 苏州源展材料科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119490487-A | Polysubstituted tetrahydrocarbazole compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-02-21 | — | — | CN | disclosed |
| EP-4482831-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | Satya Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240327381-A1 | Compounds and Compositions for Selective Degradation of Engineered Proteins | CELGENE CORPORATION (US) | 2024-10-03 | — | — | US | disclosed |
| CN-118696034-A | Novel bicyclic compounds as RAD51 inhibitors | 萨提亚疗法股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024167999-A1 | COMPOUNDS AND COMPOSITIONS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | CELGENE CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| EP-3888658-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2007053684-A2 | NEUROPROTECTIVE AGENTS | UNIVERSITY OF KANSAS (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099971-A1 | Neuroprotective agents | UNIVERSITY OF KANSAS | 2007-05-03 | — | — | US | disclosed |
| WO-2007010111-A1 | METHOD FOR PREPARING MONO- OR DIFLUORINATED HYDROCARBON COMPOUNDS | RHODIA CHIMIE (FR) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
| US-6384289-B2 | REACTING A 1,4-BIS/1,3-DIOXA-, DITHIA- OR OXATHIA- 4,5, OR 6-MEMBER CYCLOALK-2-YL/BENZENE, A FLUORINATING COMPOUND AND A BROMINE-CONTAINING COMPOUND IN A SOLVENT AT LOW TEMPERATURES; SIMPLIFICATION | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-0900772-B1 | Method for production of fluorine-containing aromatic compound | NIPPON CATALYTIC CHEM IND (JP) | 2002-04-03 | — | — | EP | disclosed |
| US-20010002425-A1 | Process for production of 1,4-bis (difluoroalkyl) benzene derivative | NIPPON SHOKUBAI CO., LTD., A JAPAN CORPORATION | 2001-05-31 | — | — | US | disclosed |
| US-6043397-A | REACTING AN AROMATIC COMPOUND HAVING CARBONYL HALIDE, ALDEHYDE OR KETONE GROUPS, AND OPTIONALLY HALOGEN GROUPS WITH A DI(ALKYL/PHENYL)AMINOSULFUR TRIFLUORIDE; REACTION CAN PROCEED IN STANDARD VESSEL AT AMBIENT TEMPERATURE, PRESSURE | NIPPON SHOKUBAI CO., LTD. (JP) | 2000-03-28 | — | — | US | disclosed |
| EP-0930287-A1 | Process for production of 1,4-bis(difluoroalkyl) benzene derivative | NIPPON SHOKUBAI CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0900772-A1 | Method for production of fluorine-containing aromatic compound | NIPPON SHOKUBAI KAGAKU KOGYO CO. LTD. (JP) | 1999-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | TYR 4650/4885DRD1 4811/4885CYP2A6 4246/4885 |
| US-20070099971-A1 | Neuroprotective agents | MAP4, MAP1LC3A, TUBB4A | TYR 3189/4885DRD1 384/4885CYP2A6 4126/4885 |
| US-20240327381-A1 | Compounds and Compositions for Selective Degradation of Engineered Proteins | TP53, APC, MDM2 | TYR 1427/4885DRD1 4816/4885CYP2A6 3700/4885 |
| US-20010002425-A1 | Process for production of 1,4-bis (difluoroalkyl) benzene derivative | AFF1, AFF2, AFF4 | TYR 1204/4885DRD1 278/4885CYP2A6 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.